|
WO2006122408A1
(en)
|
2005-05-18 |
2006-11-23 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
|
AU2006308453B9
(en)
|
2005-10-25 |
2011-12-01 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
|
TWI504597B
(zh)
|
2006-03-16 |
2015-10-21 |
Pharmascience Inc |
結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
|
|
WO2008128171A2
(en)
*
|
2007-04-13 |
2008-10-23 |
The Regents Of The University Of Michigan |
Diazo bicyclic smac mimetics and the uses thereof
|
|
ES2643233T3
(es)
|
2009-10-23 |
2017-11-21 |
The Regents Of The University Of Michigan |
Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos
|
|
CA2780130A1
(en)
*
|
2009-11-05 |
2011-05-12 |
The Uab Research Foundation |
Treating basal-like genotype cancers
|
|
NZ602368A
(en)
|
2010-02-12 |
2014-10-31 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
WO2012052758A1
(en)
|
2010-10-22 |
2012-04-26 |
Astrazeneca Ab |
Response biomarkers for iap antagonists in human cancers
|
|
GB201106817D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Astex Therapeutics Ltd |
New compound
|
|
AU2013306087B2
(en)
*
|
2012-08-23 |
2017-08-10 |
The Regents Of The University Of Michigan |
Bivalent inhibitors of IAP proteins and therapeutic methods using the same
|
|
CA2896577C
(en)
|
2012-11-30 |
2024-01-23 |
Sanford-Burnham Medical Research Institute |
Inhibitor of apoptosis protein (iap) antagonists
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
MX2016001654A
(es)
|
2013-09-09 |
2016-05-02 |
Halliburton Energy Services Inc |
Activacion de composiciones de cemento con retardo de fraguado mediante el intercambio de retardante.
|
|
WO2015109391A1
(en)
|
2014-01-24 |
2015-07-30 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Smc combination therapy for the treatment of cancer
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
JP6768522B2
(ja)
|
2014-06-04 |
2020-10-14 |
サンフォード−バーンハム メディカル リサーチ インスティテュート |
Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
|
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201506872D0
(en)
|
2015-04-22 |
2015-06-03 |
Ge Oil & Gas Uk Ltd |
Novel compounds
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
AU2017253560B2
(en)
|
2016-04-20 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
Conjugates comprising RIPK2 inhibitors
|
|
GB201610147D0
(en)
|
2016-06-10 |
2016-07-27 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
IL266842B
(en)
|
2016-12-01 |
2022-09-01 |
Arvinas Operations Inc |
History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
|
|
IL325835A
(en)
|
2016-12-23 |
2026-03-01 |
Univ Yale |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
|
US20210154184A1
(en)
|
2017-07-12 |
2021-05-27 |
Dana-Farber Cancer Institute, Inc. |
Compounds for tau protein degradation
|
|
KR20200072507A
(ko)
|
2017-10-19 |
2020-06-22 |
데비오팜 인터네셔날 에스 에이 |
암 치료를 위한 조합 제품
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
WO2019177902A1
(en)
|
2018-03-10 |
2019-09-19 |
Yale University |
Modulators of btk proteolysis and methods of use
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
WO2020027225A1
(ja)
|
2018-07-31 |
2020-02-06 |
ファイメクス株式会社 |
複素環化合物
|
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
CN119219628A
(zh)
|
2018-09-07 |
2024-12-31 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
|
|
US20210361774A1
(en)
|
2018-10-16 |
2021-11-25 |
Dana-Farber Cancer Institute, Inc. |
Degraders of wild-type and mutant forms of lrrk2
|
|
JP2022511437A
(ja)
|
2018-11-26 |
2022-01-31 |
デバイオファーム インターナショナル エス．エー． |
Ｈｉｖ感染の組み合わせ治療
|
|
US10870663B2
(en)
|
2018-11-30 |
2020-12-22 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds useful in HIV therapy
|
|
EP3911316A1
(en)
|
2019-01-17 |
2021-11-24 |
Debiopharm International SA |
Combination product for the treatment of cancer
|
|
ES3055186T3
(en)
|
2019-04-04 |
2026-02-10 |
Dana Farber Cancer Inst Inc |
Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
|
|
CN110028508B
(zh)
*
|
2019-05-16 |
2021-05-28 |
南京华威医药科技集团有限公司 |
一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂
|
|
EP3999182A1
(en)
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
JP7764027B2
(ja)
|
2019-07-31 |
2025-11-05 |
ファイメクス株式会社 |
複素環化合物
|
|
WO2021041348A1
(en)
|
2019-08-26 |
2021-03-04 |
Arvinas Operations, Inc. |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
AU2020356356A1
(en)
|
2019-09-25 |
2022-05-12 |
Debiopharm International S.A. |
Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
|
|
US12678509B2
(en)
|
2019-11-08 |
2026-07-14 |
Sanford Burnham Prebys Medical Discovery Institute |
Inhibitor of apoptosis (IAP) protein antagonists
|
|
US20230056604A1
(en)
|
2020-01-20 |
2023-02-23 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
AU2021342287A1
(en)
|
2020-09-14 |
2023-04-13 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
WO2022183006A1
(en)
|
2021-02-25 |
2022-09-01 |
Mayo Foundation For Medical Education And Research |
Compounds for programmable protein degradation and methods of use for the disease treatment
|
|
EP4308095A4
(en)
|
2021-03-15 |
2025-02-19 |
Maze Therapeutics, Inc. |
GLYCOGEN SYNTHASE 1 (GYS1) INHIBITORS AND METHODS OF USE THEREOF
|
|
WO2024022275A1
(zh)
*
|
2022-07-29 |
2024-02-01 |
苏州科睿思制药有限公司 |
Xevinapant的晶型及其制备方法和用途
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
CN118027138A
(zh)
*
|
2022-11-07 |
2024-05-14 |
南京中澳转化医学研究院有限公司 |
吡啶酮类化合物及其制备方法、药物组合物和应用
|
|
AR131299A1
(es)
*
|
2022-12-09 |
2025-03-05 |
Debiopharm Int Sa |
Nuevos inhibidores de iap, métodos para fabricarlos y usos de los mismos
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|
|
WO2024240858A1
(en)
|
2023-05-23 |
2024-11-28 |
Valerio Therapeutics |
Protac molecules directed against dna damage repair system and uses thereof
|
|
WO2026006700A1
(en)
*
|
2024-06-28 |
2026-01-02 |
Regents Of The University Of Michigan |
Pyrrolo[1,2-a]-azocine analogues as iap antagonists
|